Cargando…

Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis

BACKGROUND AND OBJECTIVES: To identify biomarkers associated with treatment response in patients with multiple sclerosis (MS) treated with the oral therapies teriflunomide, dimethyl fumarate (DMF), and fingolimod. METHODS: Serum levels of IL-6, IL-17, TNF-α, granulocyte-macrophage colony-stimulating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fissolo, Nicolás, Pappolla, Agustin, Rio, Jordi, Villar, Luisa M., Perez-Hoyos, Santiago, Sanchez, Alex, Gutierrez, Lucía, Montalban, Xavier, Comabella, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679885/ https://www.ncbi.nlm.nih.gov/pubmed/36411079 http://dx.doi.org/10.1212/NXI.0000000000200050

Ejemplares similares

Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure
por: Malhotra, Sunny, et al.
Publicado: (2023)

Circulating EZH2-positive T cells are decreased in multiple sclerosis patients
por: Malhotra, Sunny, et al.
Publicado: (2018)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

Teriflunomide and Epstein–Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response
por: Domínguez-Mozo, María Inmaculada, et al.
Publicado: (2023)

Molecular signature associated with cladribine treatment in patients with multiple sclerosis
por: Fissolo, Nicolas, et al.
Publicado: (2023)

Liquid Biopsy in Neurological Diseases
por: Malhotra, Sunny, et al.
Publicado: (2023)

Search for Specific Biomarkers of IFNβ Bioactivity in Patients with Multiple Sclerosis
por: Malhotra, Sunny, et al.
Publicado: (2011)

Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis
por: Malhotra, Sunny, et al.
Publicado: (2015)

Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-beta
por: Bustamante, Marta F., et al.
Publicado: (2013)

Immunomodulatory Effects Associated with Cladribine Treatment
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Identification of a Novel Risk Locus for Multiple Sclerosis at 13q31.3 by a Pooled Genome-Wide Scan of 500,000 Single Nucleotide Polymorphisms
por: Comabella, Manuel, et al.
Publicado: (2008)

An update of teriflunomide for treatment of multiple sclerosis
por: Oh, Jiwon, et al.
Publicado: (2013)

Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
por: Tornatore, Carlo, et al.
Publicado: (2022)

Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2014)

Role of oral teriflunomide in the management of multiple sclerosis
por: Tanasescu, Radu, et al.
Publicado: (2013)

Neuropathy in multiple sclerosis patients treated with teriflunomide
por: Kilic, Ahmet Kasim, et al.
Publicado: (2023)

CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis
por: Comabella, Manuel, et al.
Publicado: (2021)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2009)

COVID-19 in teriflunomide-treated patients with multiple sclerosis
por: Maghzi, Amir Hadi, et al.
Publicado: (2020)

Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2020)

Treatment with MOG-DNA vaccines induces CD4(+)CD25(+)FoxP3(+) regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis
por: Fissolo, Nicolás, et al.
Publicado: (2012)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Validation of semaphorin 7A and ala-β-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis
por: Cantó, Ester, et al.
Publicado: (2014)

Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells
por: Tilly, Gaëlle, et al.
Publicado: (2021)

Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis
por: Zuluaga, María I., et al.
Publicado: (2019)

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2013)

Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence
por: Bayas, Antonios, et al.
Publicado: (2015)

Safe Childbirth after Taking Teriflunomide in a Woman with Multiple Sclerosis
por: Cho, Bang-Hoon, et al.
Publicado: (2018)

Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
por: Comi, Giancarlo, et al.
Publicado: (2020)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy
por: Cohan, Stanley L, et al.
Publicado: (2019)

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial
por: Kappos, Ludwig, et al.
Publicado: (2021)

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis
por: Freedman, MS, et al.
Publicado: (2015)

Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status
por: Kallmann, Boris A., et al.
Publicado: (2021)

Teriflunomide treatment outcomes in multiple sclerosis: A Portuguese real-life experience
por: Nunes, Carla Cecília, et al.
Publicado: (2023)

A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients
por: Carvajal, René, et al.
Publicado: (2023)

Lesion topographies in multiple sclerosis diagnosis: A reappraisal
por: Arrambide, Georgina, et al.
Publicado: (2017)

Teriflunomide as a therapeutic means for myelin repair
por: Göttle, Peter, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i5m499unlnlcbavfqpbvj4a3eq